8-K: Syndax Q2 2025: Strong Sales, Profitability Path Clear

Syndax Pharmaceuticals reports robust Q2 2025 financial results driven by strong sales of Revuforj and Niktimvo, affirming its path to profitability.

Summary

• Total revenue for the second quarter of 2025 was $38.0 million.
• Revuforj net product revenue reached $28.6 million in Q2 2025, representing a 43% increase over Q1 2025.
• Niktimvo net revenue, as reported by Incyte for its first full quarter of launch, was $36.2 million, with Syndax's collaboration revenue share being $9.4 million.
• As of June 30, 2025, Syndax held $517.9 million in cash, cash equivalents, and investments, which is expected to fund the company to profitability.
• The supplemental New Drug Application (sNDA) for Revuforj in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) was granted Priority Review with a PDUFA action date of October 25, 2025.
• The net loss attributable to common stockholders for Q2 2025 was $71.8 million, or $0.83 per share.

Sentiment

Score: 8

Explanation: The filing indicates strong commercial performance for both key products, significant revenue growth, and a clear path to profitability supported by a robust cash position. Positive clinical trial updates and upcoming regulatory milestones further enhance the positive outlook, despite an increased net loss due to R&D and commercialization investments.

Positives

• Revuforj net revenue increased by 43% quarter-over-quarter to $28.6 million, demonstrating strong market uptake.
• Niktimvo generated $36.2 million in net revenue in its first full quarter of launch, significantly growing from $13.6 million in the first two months of Q1, and is already profitable to Syndax.
• The company's cash, cash equivalents, and investments of $517.9 million are expected to fund operations to profitability.
• Revuforj's sNDA for R/R mNPM1 AML received Priority Review and is under the FDA's Real-Time Oncology Review (RTOR) program, with a PDUFA date of October 25, 2025.
• New Revuforj data from the AUGMENT-101 trial showed a 48% overall response rate (ORR) and 26% complete remission (CR) plus complete remission with partial hematologic recovery (CRh) rate in R/R mNPM1 AML patients, with a median overall survival of 23.3 months among responders.
• Updated BEAT AML data for Revuforj in combination with venetoclax and azacitidine showed a 67% CR rate and 100% flow-MRD negativity rate among evaluable responders in newly diagnosed older adults.
• Robust and rapid responses were observed for Niktimvo in chronic GVHD patients in the pivotal AGAVE-201 trial, supporting its FDA approval.
• Dr. Nick Botwood was appointed as Head of Research and Development and Chief Medical Officer, bringing 25 years of industry experience.

Negatives

• Net loss attributable to common stockholders increased to $71.8 million ($0.83 per share) in Q2 2025, compared to $68.1 million ($0.80 per share) in Q2 2024.
• Research and development expenses increased to $62.2 million in Q2 2025 from $48.7 million in the comparable prior year period, primarily due to increased revumenib-related trial costs and a milestone payment.
• Selling, general and administrative expenses increased to $43.8 million in Q2 2025 from $29.1 million in the comparable prior year period, driven by increased employee-related expenses and commercial launch support for Revuforj.

Risks

• Unexpected safety or efficacy data observed during preclinical or clinical trials.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Changes to Revuforj's or Niktimvo's commercial availability.
• Changes in expected or existing competition.
• Changes in the regulatory environment.
• Failure of collaborators to support or advance collaborations or product candidates.
• Unexpected litigation or other disputes.

Future Outlook

Syndax expects its operating expense base to remain stable over the next few years. The company anticipates that its current cash, cash equivalents, and investments, combined with its expected product revenue and interest income, will enable it to reach profitability. The company is not providing revenue guidance at this time.

Management Comments

• "Syndax reported another remarkable quarter. With strong Revuforj and Niktimvo sales momentum along with our expectation for stable expenses over the next few years and more than $500 million in cash, we are well on our way to becoming a profitable company with two blockbuster products." Michael A. Metzger, Chief Executive Officer.
• "Notably, Revuforj net revenue increased 43% quarter-over-quarter, even with approximately a third of patients pausing treatment to receive a stem cell transplant. Revuforj is poised for continued growth as we further penetrate the KMT2A population and as patient recontinuations following stem cell transplantation build meaningfully." Michael A. Metzger, Chief Executive Officer.
• "Importantly, we are nearing another major inflection point with the anticipated approval of Revuforj as the first therapy for R/R mNPM1 AML. Longer-term, our leadership in the menin space positions us to be first to the frontline and meaningfully expand the franchise." Michael A. Metzger, Chief Executive Officer.
• "Additionally, Niktimvo is off to a very fast start generating $50 million in net revenue in just the first five months of the launch. It is already profitable to Syndax and we expect increasing profitability margins as revenues continue to grow. The impressive results demonstrate the benefit of delivering a novel approach to treating chronic GVHD and the potential for Niktimvo to transform patient care and make a substantial financial impact for Syndax." Michael A. Metzger, Chief Executive Officer.

Industry Context

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies. The company positions itself with two 'first-in-class' and 'best-in-class' medicines, Revuforj and Niktimvo, addressing significant unmet medical needs. It targets a total addressable market (TAM) of over $10 billion across relapsed/refractory and frontline indications for its products. Specifically, Revuforj is positioned in the menin inhibition space for acute leukemia, a $5B+ TAM, while Niktimvo's initial indication in chronic GVHD represents a $2B U.S. market opportunity, with potential for expansion into newly diagnosed cGVHD and idiopathic pulmonary fibrosis (IPF).

Comparison to Industry Standards

• Revuforj is highlighted as a first-in-class menin inhibitor, positioning Syndax as a leader in this therapeutic area with a potential $5B+ total addressable market.
• Niktimvo is described as a first-in-class CSF-1R-blocking antibody, addressing a $2B U.S. market opportunity in chronic GVHD, with ongoing trials to expand into newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis (IPF).
• The company's collaborations with leading clinical trial groups like the HOVON network, the Leukemia & Lymphoma Society's Beat AML Master Clinical Trial, and MD Anderson Cancer Center, demonstrate its engagement with established industry research standards for novel therapies in hematologic malignancies.

Management Changes

Related Party Transactions

• Syndax and Incyte co-commercialize Niktimvo, with Syndax recording 50% of the Niktimvo net commercial profit/loss. This collaboration is highlighted, especially given the resignation of William Meury from Syndax's board to become CEO of Incyte.

Stakeholder Impact

• Shareholders: Positive impact due to strong product sales growth, a clear path to profitability, and significant pipeline advancements, potentially leading to increased shareholder value.
• Patients: Enhanced access to innovative, first-in-class therapies for acute leukemia (Revuforj) and chronic graft-versus-host disease (Niktimvo), with ongoing trials to expand treatment options.
• Employees: Increased personnel costs suggest company growth and potential for stable employment, particularly in commercial and R&D functions.
• Incyte (Collaboration Partner): Continued shared success and profitability from the co-commercialization of Niktimvo, reinforcing the partnership.

Next Steps

• PDUFA action date for Revuforj's sNDA for R/R mNPM1 AML is October 25, 2025.
• Expect to report data from the Phase 1 trial evaluating revumenib with intensive chemotherapy in the fourth quarter of 2025.
• Trial initiation for the REVEAL trials, evaluating revumenib in combination with standard of care in newly diagnosed acute leukemia patients, is expected in the fourth quarter of 2025.
• Expect to report data from the trial evaluating revumenib in R/R metastatic MSS colorectal cancer by the end of 2025.
• Expect to complete enrollment in the MAXPIRe trial (axatilimab in IPF) in the fourth quarter of 2025.
• Topline data from the MAXPIRe trial are anticipated in the second half of 2026.
• The company will host a conference call on August 4, 2025, at 4:30 p.m. ET to discuss the results.

Key Dates

Recommendation

The company demonstrated exceptional commercial execution with both Revuforj and Niktimvo, significantly exceeding sales expectations and establishing a clear path to profitability. The strong cash position, coupled with a stable expense outlook, provides financial stability. Furthermore, the upcoming PDUFA date for Revuforj in R/R mNPM1 AML represents a major near-term catalyst, potentially expanding its market significantly. The robust clinical data across multiple indications for both assets reinforces their 'first-in-class' and 'best-in-class' potential in large, unmet medical need markets.

Keywords

Oncology, Biopharmaceutical, Cancer Therapy, Acute Leukemia, Chronic GVHD, Menin Inhibitor, CSF-1R Antibody, Revuforj, Revumenib, Niktimvo, Axatilimab, AML, mNPM1, KMT2A, Graft-versus-host disease, IPF, Financial Results, Q2 2025